Intervention

Temozolomide

ClinicalTrials.gov intervention label

Clinical trials33
Recruiting3
Common conditions25
Lead sponsors shown15

Clinical trials

33 shown
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680 · 2026-07-27
RECRUITING
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung CancerNCT06931626 · 2025-08-15
RECRUITING
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung CancerNCT04919382 · 2022-01-26
RECRUITING
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasNCT06202066 · 2026-10-15
SUSPENDED
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)NCT05128734 · 2026-04-01
NOT_YET_RECRUITING
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNCT07141771 · 2025-12-31
NOT_YET_RECRUITING
HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung CancerNCT05728619 · 2023-02-03
UNKNOWN
A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsNCT04478279 · 2020-07-01
ACTIVE_NOT_RECRUITING
A Study of the Drugs Talazoparib and Temozolomide in Prostate CancerNCT04019327 · 2019-07-11
TERMINATED
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line ChemotherapyNCT03830918 · 2019-03-06
ACTIVE_NOT_RECRUITING
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerNCT03728361 · 2018-12-31
COMPLETED
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerNCT03672773 · 2018-10-31
ACTIVE_NOT_RECRUITING
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung CancersNCT03554473 · 2018-09-11
COMPLETED
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid TumorsNCT03150810 · 2017-06-28
COMPLETED
Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung CancerNCT02772107 · 2015-12-01
UNKNOWN
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior ChemotherapyNCT02446704 · 2015-10-13
UNKNOWN
Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT MethylationNCT02477813 · 2015-01-01
TERMINATED
Temozolomide as Maintenance Therapy in Small Cell Lung CancerNCT01900951 · 2013-01-01
UNKNOWN
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)NCT01704287 · 2012-11-20
COMPLETED
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung CancerNCT01638546 · 2012-07-27
ACTIVE_NOT_RECRUITING
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast CancerNCT01506609 · 2012-01-23
COMPLETED
Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung CancerNCT00740636 · 2008-08-01
COMPLETED
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)NCT00632203 · 2008-03-04
TERMINATED
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer PatientsNCT00526617 · 2007-08-01
COMPLETED
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)NCT00423150 · 2007-01-26
TERMINATED
Aerosol L9-NC and Temozolomide in Ewing's SarcomaNCT00492141 · 2006-06-01
COMPLETED
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung CancerNCT00080938 · 2005-12-20
COMPLETED
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung CancerNCT00096265 · 2004-10-06
TERMINATED
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) MalignancyNCT00629187 · 2004-04-01
TERMINATED
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)NCT00076856 · 2004-03-31
COMPLETED
Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)NCT00831545 · 2000-12-01
COMPLETED
Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast CancerNCT00194766 · 2000-07-01
COMPLETED
Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung CancerNCT00005037 · 2000-01-01
COMPLETED

Common conditions

Carcinoma, Non-Small-Cell Lung4Lung Cancer4Breast Cancer3Small Cell Lung Cancer3Carcinoma, Small Cell2Extensive Stage Lung Small Cell Carcinoma2Metastatic Breast Cancer2Metastatic Melanoma2Neoplasm Metastasis2Prostate Cancer2Prostate Cancer Metastatic2Recurrent Extensive Stage Small Cell Lung Carcinoma2Recurrent Lung Small Cell Carcinoma2Stage IV Lung Cancer AJCC v82Stage IVA Lung Cancer AJCC v82Stage IVB Lung Cancer AJCC v82Adenocarcinoma1Advanced Malignant Solid Neoplasm1Brain Cancer1Brain Neoplasms1Breast Cancer Triple Negative1Breast Neoplasm1Carcinoma, Large Cell1Carcinoma, Squamous Cell1Castration-resistant Prostate Cancer1

Trial status mix

COMPLETED13
TERMINATED6
ACTIVE_NOT_RECRUITING4
UNKNOWN4
RECRUITING3
NOT_YET_RECRUITING2
SUSPENDED1

Phase mix

PHASE228
PHASE112
PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.